Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01872689
Registration number
NCT01872689
Ethics application status
Date submitted
5/06/2013
Date registered
7/06/2013
Date last updated
24/08/2018
Titles & IDs
Public title
A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Query!
Scientific title
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Query!
Secondary ID [1]
0
0
2013-001163-24
Query!
Secondary ID [2]
0
0
GB28547
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Lebrikizumab
Treatment: Drugs - Pirfenidone
Treatment: Drugs - Placebo
Placebo comparator: Monotherapy (Cohort A): Placebo - Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
Experimental: Monotherapy (Cohort A): Lebrikizumab - Participants will receive monotherapy with lebrikizumab at a dose of 250 milligrams (mg) administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
Placebo comparator: Combination Therapy (Cohort B): Placebo + Pirfenidone - Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day \[9 capsules daily\] for a total of 2403 mg/day) or at maximum tolerated dose (MTD) administered orally along with placebo matched to lebrikizumab administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
Experimental: Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone - Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day \[9 capsules daily\] for a total of 2403 mg/day) or at MTD administered orally along with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
Treatment: Drugs: Lebrikizumab
Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
Treatment: Drugs: Pirfenidone
Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
Treatment: Drugs: Placebo
Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Annualized Rate of Decrease in Percent Predicted Forced Vital Capacity (FVC) Over 52 Weeks
Query!
Assessment method [1]
0
0
Annualized rates of decrease (slope throughout time from baseline to Week 52) for percent predicted FVC was assessed and reported. FVC is a standard pulmonary function test. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.
Query!
Timepoint [1]
0
0
Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Query!
Secondary outcome [1]
0
0
Annualized Rate of Decline in 6-Minute Walk Test (6MWT) Distance Over 52 Weeks
Query!
Assessment method [1]
0
0
Annualized rates of decline (slope throughout time from baseline to Week 52) in 6MWT was assessed and reported. 6MWT was the distance (in meters \[m\]) that a participant could walk in 6 minutes.
Query!
Timepoint [1]
0
0
Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Event of Greater Than or Equal to (>/=) 10% Absolute Decline in Percent Predicted FVC or Death From Any Cause
Query!
Assessment method [2]
0
0
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.
Query!
Timepoint [2]
0
0
Baseline up to the event of >/=10% absolute decline in percent predicted FVC or death from any cause, whichever occurred first (up to Week 122)
Query!
Secondary outcome [3]
0
0
Time to First Occurrence of a >/=10% Absolute Decline in Percent Predicted FVC or Death From Any Cause
Query!
Assessment method [3]
0
0
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100. Time from randomization to first occurrence of an event of \>/=10% absolute decline in percent predicted FVC or death from any cause was reported. Participants without an event were censored at the last assessment during the double-blind treatment period. Any participant who underwent lung transplantation was censored at the date of the transplant. The median time to event was estimated using Kaplan-Meier method. 95% confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [3]
0
0
Baseline up to the event of >/=10% absolute decline in percent predicted FVC or death from any cause, whichever occurred first (up to Week 122)
Query!
Secondary outcome [4]
0
0
Annualized Rate of Decrease in Diffusion Capacity of the Lung for Carbon Monoxide (DLco) Over 52 Weeks
Query!
Assessment method [4]
0
0
Annualized rates of decrease (slope throughout time from baseline to Week 52) in DLco was assessed and reported. DLco (in milliliters per minute/millimeters of mercury \[mL/min/mmHg\]) is a measure of the gas transfer.
Query!
Timepoint [4]
0
0
Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Event of Death, All Cause Hospitalization, or a Decrease From Baseline of >/=10% in FVC
Query!
Assessment method [5]
0
0
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC = \[(observed FVC)/(predicted FVC)\]\*100.
Query!
Timepoint [5]
0
0
Baseline up to the event of death from any cause, all cause hospitalization, or a decrease from baseline of >/=10% in FVC, whichever occurred first (up to Week 122)
Query!
Secondary outcome [6]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [6]
0
0
FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC = \[(observed FVC)/(predicted FVC)\]\*100. PFS was defined as time from randomization to death from any cause, all cause hospitalization, or a decrease from baseline of \>/=10% in FVC, whichever occurred first. Participants without an event were censored at the last assessment during the double-blind treatment period. Any participant who underwent lung transplantation was censored at the date of the transplant. The median PFS was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [6]
0
0
Baseline up to the event of death from any cause, all cause hospitalization, or a decrease from baseline of >/=10% in FVC, whichever occurred first (up to Week 122)
Query!
Secondary outcome [7]
0
0
Annualized Rate of Decrease in FVC Over 52 Weeks
Query!
Assessment method [7]
0
0
Annualized rates of decrease (slope throughout time from baseline to Week 52) in FVC (in milliliters per year \[mL/year\]) was assessed and reported. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position.
Query!
Timepoint [7]
0
0
Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Query!
Secondary outcome [8]
0
0
Annualized Rate of Decrease in A Tool to Assess Quality of Life in IPF (ATAQ-IPF) Questionnaire Total Score Over 52 Weeks
Query!
Assessment method [8]
0
0
The ATAQ-IPF Version 3 was utilized that included 31 items within 5 domains: cough (6 items), dyspnea (7 items), exhaustion (6 items), emotional well-being (6 items), and independence (6 items). Each item was assessed on a scale ranging from 1 (Strongly disagree) to 4 (Strongly agree). The ATAQ-IPF had a recall specification of 2 weeks. Simple summation scoring was used to derive individual domain scores as well as a total score. ATAQ-IPF total score ranged from 31 to 124 with lower score indicating better quality of life (QoL). Annualized rates of decrease (slope throughout time from baseline to Week 52) in ATAQ-IPF questionnaire total score was assessed and reported.
Query!
Timepoint [8]
0
0
Baseline up to Week 52 (assessed at Baseline, Weeks 1, 4, 12, 24, 36, 44, and 52)
Query!
Secondary outcome [9]
0
0
Percentage of Participants With an Event of St. George's Respiratory Questionnaire (SGRQ) Total Score Worsening or Death From Any Cause
Query!
Assessment method [9]
0
0
The SGRQ is a 50-item health-related QoL instrument that measured health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks. The SGRQ total score (summed weights) ranged from 0 to 100 with a lower score denoting a better health status. Percentage of participants with an event of SGRQ total score worsening (defined as reaching minimal important difference \[MID\], that is, an increase in total score of \>/=7) or death from any cause was reported.
Query!
Timepoint [9]
0
0
Baseline up to the event of SGRQ total score worsening or death from any cause, whichever occurred first (up to Week 122)
Query!
Secondary outcome [10]
0
0
Time to First Occurrence of SGRQ Total Score Worsening or Death From Any Cause
Query!
Assessment method [10]
0
0
The SGRQ is a 50-item health-related QoL instrument that measured health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. The SGRQ had a recall specification of 4 weeks. The SGRQ total score (summed weights) ranged from 0 to 100 with a lower score denoting a better health status. Time from randomization to first occurrence of an event of SGRQ total score worsening (defined as reaching minimal important difference \[MID\], that is, an increase in total score of \>/=7) or death from any cause was reported. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [10]
0
0
Baseline up to the event of SGRQ total score worsening or death from any cause, whichever occurred first (up to Week 122)
Query!
Secondary outcome [11]
0
0
Percentage of Participants With an Event of Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
Query!
Assessment method [11]
0
0
IPF exacerbation was defined as an event that met all of the following criteria as determined by the investigator: Unexplained worsening or development of dyspnea within the previous 30 days; And radiologic evidence of new bilateral ground-glass abnormality or consolidation, superimposed on a reticular or honeycomb background pattern, that is consistent with usual interstitial pneumonitis; And absence of alternative causes, such as left heart failure, pulmonary embolism, pulmonary infection (on the basis of endotracheal aspirate or bronchoalveolar lavage if available, or investigator judgment), or other events leading to acute lung injury (for example, sepsis, aspiration, trauma, reperfusion pulmonary edema).
Query!
Timepoint [11]
0
0
Baseline up to the event of acute IPF exacerbation (up to Week 122)
Query!
Secondary outcome [12]
0
0
Time to First Event of Acute IPF Exacerbation
Query!
Assessment method [12]
0
0
Time from randomization to first occurrence of an event of IPF exacerbation was reported. IPF exacerbation was defined as an event that met all of the following criteria as determined by the investigator: Unexplained worsening or development of dyspnea within the previous 30 days; And radiologic evidence of new bilateral ground-glass abnormality or consolidation, superimposed on a reticular or honeycomb background pattern, that is consistent with usual interstitial pneumonitis; And absence of alternative causes, or other events leading to acute lung injury. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [12]
0
0
Baseline up to the event of acute IPF exacerbation (up to Week 122)
Query!
Secondary outcome [13]
0
0
Percentage of Participants With Respiratory-Related Hospitalization
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Baseline up to the event of respiratory-related hospitalization (up to Week 122)
Query!
Secondary outcome [14]
0
0
Time to Respiratory-Related Hospitalization
Query!
Assessment method [14]
0
0
Time from randomization to first occurrence of an event of respiratory-related hospitalization was reported. Participants without an event were censored at the last known alive day, study Day 368, or the last date during the double-blind period. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [14]
0
0
Baseline up to the event of respiratory-related hospitalization (up to Week 122)
Query!
Secondary outcome [15]
0
0
Percentage of Participants With an Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause
Query!
Assessment method [15]
0
0
DLco (in mL/min/mmHg) is a measure of the gas transfer. Predicted DLco is based on sex, age, and height of a person. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100.
Query!
Timepoint [15]
0
0
Baseline up to the event of >/=15% absolute decrease in percentage of predicted DLco or death from any cause (up to Week 122)
Query!
Secondary outcome [16]
0
0
Time to First Event of >/=15% Absolute Decrease in Percentage of Predicted DLco or Death From Any Cause
Query!
Assessment method [16]
0
0
DLco is a measure of the gas transfer. Predicted DLco is based on sex, age, and height of a person. Percent of predicted DLco (in %) = \[(observed DLco)/(predicted DLco)\]\*100. Time from randomization to first occurrence of \>/=15% absolute decrease in percentage of predicted DLco or death from any cause was reported. The median time to event was estimated using Kaplan-Meier method. 95% CI for median was computed using the method of Brookmeyer and Crowley.
Query!
Timepoint [16]
0
0
Baseline up to the event of >/=15% absolute decrease in percentage of predicted DLco or death from any cause (up to Week 122)
Query!
Secondary outcome [17]
0
0
Percentage of Participants With Anti-therapeutic Antibody (ATA) to Lebrikizumab
Query!
Assessment method [17]
0
0
ATA to lebrikizumab was tested using a validated immunoassay. A positive ATA result was defined as one in which the presence of detectable ATAs could be confirmed by competitive binding with lebrikizumab. Percentage of participants with positive results for ATA at Baseline and at post-baseline time points were reported. Only participants who received lebrikizumab were included in the analysis.
Query!
Timepoint [17]
0
0
Baseline and Post-Baseline (assessed at multiple time points: Weeks 4, 12, 24, 36, 52, 56, 64, 76, and at safety follow-up up to Week 122)
Query!
Secondary outcome [18]
0
0
Minimum Observed Serum Concentration (Cmin) of Lebrikizumab at Week 52
Query!
Assessment method [18]
0
0
Participants who received lebrikizumab were only included in the analysis.
Query!
Timepoint [18]
0
0
Predose (Hour 0) at Week 52
Query!
Secondary outcome [19]
0
0
Minimum Observed Serum Concentration (Cmin) of Lebrikizumab
Query!
Assessment method [19]
0
0
Participants who received lebrikizumab were only included in the analysis.
Query!
Timepoint [19]
0
0
Predose (Hour 0) at Weeks 4, 12, 24, and 36
Query!
Secondary outcome [20]
0
0
Elimination Half-Life (t1/2) of Lebrikizumab
Query!
Assessment method [20]
0
0
Elimination half-life is the time measured for the plasma drug concentration to decrease by one-half during the elimination phase of the drug. Analysis was performed on PK-Evaluable Population. Participants who received lebrikizumab were only included in the analysis.
Query!
Timepoint [20]
0
0
Pre-dose (Hour 0) at Weeks 1, 4, 12, 24, 36, 64, 76, 88, 104; and at 4, 12, and 18 weeks post-last dose (last dose = Week 104)
Query!
Eligibility
Key inclusion criteria
* Have a diagnosis of IPF within the previous 5 years from time of screening and confirmed at baseline
* FVC >/=40 percent (%) and </=100% of predicted at screening
* Stable baseline lung function as evidenced by a difference of less than (<) 10% in FVC (in liters) measurements between screening and Day 1, Visit 2 prior to randomization
* DLco >/=25% and </=90% of predicted at screening
* Ability to walk >/=100 meters unassisted in 6 minutes
* Cohort A: No background IPF therapy for >/=4 weeks allowed prior to randomization and throughout the placebo-controlled study period
* Cohort B: Tolerated dose of pirfenidone </=2403 milligrams once daily (mg/day) for >/=4 weeks required prior to randomization and throughout the placebo-controlled study period
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection
* Evidence of other known causes of interstitial lung disease
* Lung transplant expected within 12 months of screening
* Evidence of clinically significant lung disease other than IPF
* Post-bronchodilator forced expiratory volume in 1 second (FEV1)/FVC ratio <0.7 at screening
* Positive bronchodilator response, evidenced by an increase of >/=12% predicted and 200 milliliters increase in FEV1 or FVC
* Class IV New York Heart Association chronic heart failure or historical evidence of left ventricular ejection fraction <35%
* Hospitalization due to an exacerbation of IPF within 4 weeks prior to or during screening
* Known current malignancy or current evaluation for potential malignancy
* Listeria monocytogenes infection or active parasitic infection within 6 months prior to Day 1, Visit 2
* Active tuberculosis requiring treatment within 12 months of screening
* Known immunodeficiency, including but not limited to human immunodeficiency virus infection
* Past use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy, including lebrikizumab
* Evidence of acute or chronic hepatitis or known liver cirrhosis
Exclusions Criteria Limited to Cohort B:
* Known achalasia, esophageal stricture, or esophageal dysfunction sufficient to limit the ability to swallow oral medication
* Tobacco smoking or use of tobacco-related products within 3 months of screening or unwillingness to avoid smoking throughout the study period
* Known or suspected peptic ulcer
* Any condition that, as assessed by the investigator, might be significantly exacerbated by the known side effects associated with pirfenidone
* Creatinine clearance <40 milliliters/minute, calculated using the Cockcroft-Gault formula
* Use of following therapies within 4 weeks of randomization (Day 1, Visit 2) or during the study: Strong inhibitors of CYP1A2 (Cytochrome P450 Family 1 Subfamily A Member 2) (example: fluvoxamine or enoxacin); Moderate inducers of CYP1A2 (limited to tobacco smoking and tobacco-related products)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/10/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
6/11/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
505
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital; Department of Respiratory Medicine - Camperdown
Query!
Recruitment hospital [2]
0
0
ST VINCENT'S HOSPITAL; Thoracic Medicine - Darlinghurst
Query!
Recruitment hospital [3]
0
0
Box Hill Hospital; Eastern Clinical Research Unit - Box Hill
Query!
Recruitment hospital [4]
0
0
Alfred Hospital; Allergy Immuno Resp - Melbourne
Query!
Recruitment hospital [5]
0
0
Institute for Respiratory Health Inc - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maine
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Minnesota
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nebraska
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Mexico
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oklahoma
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Rhode Island
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Tennessee
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Texas
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Utah
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Vermont
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Virginia
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Washington
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Wisconsin
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Bruxelles
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Leuven
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Mont-godinne
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
British Columbia
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
New Brunswick
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Ontario
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Quebec
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Bobigny
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Bron
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Lille
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Paris
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Rennes
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Essen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Gießen
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Großhansdorf
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Heidelberg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Immenhausen
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
München
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Emilia-Romagna
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Lazio
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Lombardia
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Piemonte
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Sicilia
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Toscana
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Kanagawa
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Osaka
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Seto-shi
Query!
Country [59]
0
0
Mexico
Query!
State/province [59]
0
0
Hermosillo
Query!
Country [60]
0
0
Mexico
Query!
State/province [60]
0
0
Mexico City
Query!
Country [61]
0
0
Mexico
Query!
State/province [61]
0
0
Monterrey
Query!
Country [62]
0
0
Peru
Query!
State/province [62]
0
0
Lima
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Lodz
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Lublin
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Poznan
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Warszawa
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Zabrze
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Barcelona
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Madrid
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Sevilla
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Valencia
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
Bristol
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
Cambridge
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
Hampshire
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Leeds
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Liverpool
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
London
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy and as combination therapy with pirfenidone background therapy in participants with IPF. Participants will be randomized to receive either lebrikizumab or placebo subcutaneously every 4 weeks.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01872689
Query!
Trial related presentations / publications
Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, Schwartz DA, Maher TM, Flores C, Noth I, Yaspan BL, Jenkins RG, Wain LV; International IPF Genetics Consortium. Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax. 2022 Aug;77(8):829-833. doi: 10.1136/thoraxjnl-2021-218577. Epub 2022 Jun 10.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/89/NCT01872689/Prot_SAP_000.pdf
Statistical analysis plan
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/89/NCT01872689/Prot_SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01872689
Download to PDF